Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains
- PMID: 19920089
- PMCID: PMC2815653
- DOI: 10.1093/glycob/cwp184
Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains
Abstract
Design of an envelope glycoprotein (Env)-based vaccine against human immunodeficiency virus type-1 (HIV-1) is complicated by the large number of N-linked glycans that coat the protein and serve as a barrier to antibody-mediated neutralization. Compared to normal mammalian glycoproteins, high-mannose-type glycans are disproportionately represented on the gp120 subunit of Env. These N-glycans serve as a target for a number of anti-HIV molecules that bind terminal alpha1,2-linked mannose residues, including lectins and the monoclonal antibody 2G12. We created a Saccharomyces cerevisiae glycosylation mutant, Deltamnn1Deltamnn4, to expose numerous terminal Manalpha1,2-Man residues on endogenous hypermannosylated glycoproteins in the yeast cell wall. Immunization of rabbits with whole cells from this mutant induced antibodies that bound to a broad range of Env proteins, including clade A, B, and C of HIV and simian immunodeficiency virus (SIV). The gp120 binding activity of these immune sera was due to mannose-specific immunoglobulin, as removal of high-mannose glycans and alpha1,2-linked mannoses from gp120 abrogated serum binding. Glycan array analysis with purified IgG demonstrated binding mainly to glycans with Manalpha1,2-Manalpha1,2-Man trisaccharides. Altogether, these data demonstrate the immunogenicity of exposed polyvalent Manalpha1,2-Manalpha1,2-Man structures on the yeast cell wall mannan and their ability to induce antibodies that bind to the HIV Env protein. The yeast strain and sera from this study will be useful tools for determining the type of mannose-specific response that is needed to develop neutralizing antibodies to the glycan shield of HIV.
Figures




Similar articles
-
An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.J Virol. 2008 Jul;82(13):6447-57. doi: 10.1128/JVI.00412-08. Epub 2008 Apr 23. J Virol. 2008. PMID: 18434410 Free PMC article.
-
A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.J Virol. 2009 May;83(10):4861-70. doi: 10.1128/JVI.02537-08. Epub 2009 Mar 4. J Virol. 2009. PMID: 19264785 Free PMC article.
-
Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.J Virol. 2011 Jan;85(1):470-80. doi: 10.1128/JVI.01349-10. Epub 2010 Oct 20. J Virol. 2011. PMID: 20962094 Free PMC article.
-
Antibody responses to the HIV-1 envelope high mannose patch.Adv Immunol. 2019;143:11-73. doi: 10.1016/bs.ai.2019.08.002. Epub 2019 Sep 11. Adv Immunol. 2019. PMID: 31607367 Free PMC article. Review.
-
GP120: target for neutralizing HIV-1 antibodies.Annu Rev Immunol. 2006;24:739-69. doi: 10.1146/annurev.immunol.24.021605.090557. Annu Rev Immunol. 2006. PMID: 16551265 Review.
Cited by
-
Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.AIDS Res Hum Retroviruses. 2013 Nov;29(11):1407-17. doi: 10.1089/AID.2013.0102. Epub 2013 Jul 19. AIDS Res Hum Retroviruses. 2013. PMID: 23767872 Free PMC article.
-
Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.J Virol. 2010 Oct;84(20):10690-9. doi: 10.1128/JVI.01110-10. Epub 2010 Aug 11. J Virol. 2010. PMID: 20702629 Free PMC article.
-
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13800-5. doi: 10.1073/pnas.1006498107. Epub 2010 Jul 19. Proc Natl Acad Sci U S A. 2010. PMID: 20643940 Free PMC article.
-
Glycan Reactive Natural Antibodies and Viral Immunity.Viral Immunol. 2020 May;33(4):266-276. doi: 10.1089/vim.2019.0136. Epub 2019 Dec 17. Viral Immunol. 2020. PMID: 31851873 Free PMC article. Review.
-
High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.J Virol. 2012 Feb;86(4):2153-64. doi: 10.1128/JVI.06201-11. Epub 2011 Dec 7. J Virol. 2012. PMID: 22156525 Free PMC article.
References
-
- Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol. 2008;82:6359–6368. - PMC - PubMed
-
- Ballou CE. Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods Enzymol. 1990;185:440–470. - PubMed
-
- Balzarini J. Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis. 2005;5:726–731. - PubMed
-
- Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233–236. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases